Trial Profile

An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult male patients with Tourette Syndrome (TS)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Dec 2024 According to a Noema Pharma media release, key readout from this trial expected in 2025.
17 Oct 2024 Results published in the Noema Pharma media release
17 Oct 2024 According to a Noema Pharma media release, Primary endpoint (Response to the investigational drug NOE-105 rated by the Tourette Syndrome Clinical Global Impression of Change (TS-CGI-C). Response is defined as a rating of Minimally improved Much improved and Very much improved) has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com